Who Buys Formoterol from India — 320 Importers Behind a $57.4M Market

The importation of Formoterol from India involves various buyer segments, each with distinct purchasing behaviors:

• Distributors: Entities like LIFESTAR PHARMA LLC and CIPLA USA INC UPS SUPPLY CHAIN SOLU in the United States function as intermediaries, procuring large quantities to supply to healthcare providers and pharmacies. Their substantial purchase volumes indicate a focus on maintaining a steady supply chain to meet market demand.

• Contract Manufacturers: Companies such as SUN PHARMACEUTICAL INDUSTRIES INC in the United States likely import Formoterol as an active pharmaceutical ingredient (API) for the production of finished dosage forms. Their procurement patterns are aligned with production schedules and market demand forecasts.

• Re-exporters: Entities like H.ESSERS & ZONEN INTERNATIONAL TRA in Belgium may import Formoterol for distribution to other markets, leveraging strategic geographic positions to serve broader regions.

• Government Procurement Agencies: Organizations such as BREATHEFREE LANKA PVT LTD in Sri Lanka may be involved in government tenders, procuring Formoterol for public health programs. Their purchasing is often characterized by bulk orders aligned with national healthcare initiatives.

Each segment's procurement strategies are influenced by factors such as regulatory requirements, market demand, and supply chain logistics, resulting in varied order sizes and frequencies.

United States

1. Regulatory Authority: U.S. Food and Drug Administration (FDA).

2. Import Registration Process: Importers must ensure that Formoterol is FDA-approved. This involves submitting a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) for generic versions.

3. Estimated Timeline for Registration: The FDA review process typically takes 10 months for standard applications, though priority reviews can be expedited to 6 months.

4. Import Tariff/Duty for HS 30049099: Pharmaceutical products under this HS code are generally duty-free in the U.S.

Sri Lanka

1. Regulatory Authority: National Medicines Regulatory Authority (NMRA).

2. Import Registration Process: Importers must obtain registration from the NMRA, which includes submitting product dossiers and samples for evaluation.

3. Estimated Timeline for Registration: The registration process can take approximately 6 to 12 months, depending on the completeness of the application and the need for additional information.

4. Import Tariff/Duty for HS 30049099: Pharmaceuticals are subject to a duty of 0% to 15%, depending on the product and applicable trade agreements.

Algeria

1. Regulatory Authority: Agence Nationale des Produits Pharmaceutiques (ANPP).

2. Import Registration Process: Requires submission of a registration dossier, including clinical data and manufacturing details, to the ANPP.

3. Estimated Timeline for Registration: The process can take 12 to 24 months, influenced by the complexity of the product and regulatory workload.

4. Import Tariff/Duty for HS 30049099: Pharmaceutical products may be subject to a Value Added Tax (VAT) of 19%, with import duties varying based on specific product classifications.

Belgium

1. Regulatory Authority: Federal Agency for Medicines and Health Products (FAMHP).

2. Import Registration Process: Medicines must be authorized by the European Medicines Agency (EMA) or FAMHP. Importers need a wholesale distribution authorization.

3. Estimated Timeline for Registration: The EMA's centralized procedure takes up to 210 days, while national procedures can vary but generally align with this timeframe.

4. Import Tariff/Duty for HS 30049099: Pharmaceuticals imported into Belgium are typically duty-free but subject to a VAT of 6%.

Dominican Republic

1. Regulatory Authority: Dirección General de Medicamentos, Alimentos y Productos Sanitarios (DIGEMAPS).

2. Import Registration Process: Requires submission of a registration dossier, including product samples and manufacturing information, to DIGEMAPS.

3. Estimated Timeline for Registration: The process can take 6 to 12 months, depending on the complexity of the product and the completeness of the application.

4. Import Tariff/Duty for HS 30049099: Pharmaceutical products are generally subject to a 0% import duty but may incur a VAT of 18%.

The demand for Formoterol, a long-acting β₂-agonist used in managing asthma and chronic obstructive pulmonary disease (COPD), is driven by several factors:

• Disease Prevalence: The global burden of respiratory diseases is significant. According to the World Health Organization (WHO), COPD was the third leading cause of death worldwide in 2019, causing 3.23 million deaths. Asthma affected an estimated 262 million people in the same year.

• Government Healthcare Programs: Many countries have implemented national health programs focusing on non-communicable diseases, including respiratory conditions. For instance, the United States' National Asthma Control Program aims to reduce the burden of asthma through surveillance and intervention strategies.

• Universal Health Coverage Expansion: Efforts to achieve universal health coverage have led to increased access to essential medicines. Countries like Sri Lanka have made significant strides in providing free or subsidized medications for chronic diseases through public health services.

• WHO Essential Medicines List Procurement: Formoterol is included in the WHO Model List of Essential Medicines, guiding countries in prioritizing procurement to ensure availability of critical treatments.

• Tender-Based Purchasing: Many governments and large healthcare providers procure medicines through competitive tendering processes, aiming to secure quality products at optimal prices. This approach is prevalent in countries like Algeria and Belgium, influencing the importation and distribution of Formoterol.

With 320 buyers across 81 countries, the market for Formoterol reflects a global need for effective respiratory treatments, underscoring opportunities for suppliers to meet diverse healthcare demands.

The importation of Formoterol from India involves various buyer segments, each with distinct purchasing behaviors:

• Distributors: Entities like LIFESTAR PHARMA LLC and CIPLA USA INC UPS SUPPLY CHAIN SOLU in the United States function as intermediaries, procuring large quantities to supply to healthcare providers and pharmacies. Their substantial purchase volumes indicate a focus on maintaining a steady supply chain to meet market demand.

• Contract Manufacturers: Companies such as SUN PHARMACEUTICAL INDUSTRIES INC in the United States likely import Formoterol as an active pharmaceutical ingredient (API) for the production of finished dosage forms. Their procurement patterns are aligned with production schedules and market demand forecasts.

• Re-exporters: Entities like H.ESSERS & ZONEN INTERNATIONAL TRA in Belgium may import Formoterol for distribution to other markets, leveraging strategic geographic positions to serve broader regions.

• Government Procurement Agencies: Organizations such as BREATHEFREE LANKA PVT LTD in Sri Lanka may be involved in government tenders, procuring Formoterol for public health programs. Their purchasing is often characterized by bulk orders aligned with national healthcare initiatives.

Each segment's procurement strategies are influenced by factors such as regulatory requirements, market demand, and supply chain logistics, resulting in varied order sizes and frequencies.

United States

1. Regulatory Authority: U.S. Food and Drug Administration (FDA).

2. Import Registration Process: Importers must ensure that Formoterol is FDA-approved. This involves submitting a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) for generic versions.

3. Estimated Timeline for Registration: The FDA review process typically takes 10 months for standard applications, though priority reviews can be expedited to 6 months.

4. Import Tariff/Duty for HS 30049099: Pharmaceutical products under this HS code are generally duty-free in the U.S.

Sri Lanka

1. Regulatory Authority: National Medicines Regulatory Authority (NMRA).

2. Import Registration Process: Importers must obtain registration from the NMRA, which includes submitting product dossiers and samples for evaluation.

3. Estimated Timeline for Registration: The registration process can take approximately 6 to 12 months, depending on the completeness of the application and the need for additional information.

4. Import Tariff/Duty for HS 30049099: Pharmaceuticals are subject to a duty of 0% to 15%, depending on the product and applicable trade agreements.

Algeria

1. Regulatory Authority: Agence Nationale des Produits Pharmaceutiques (ANPP).

2. Import Registration Process: Requires submission of a registration dossier, including clinical data and manufacturing details, to the ANPP.

3. Estimated Timeline for Registration: The process can take 12 to 24 months, influenced by the complexity of the product and regulatory workload.

4. Import Tariff/Duty for HS 30049099: Pharmaceutical products may be subject to a Value Added Tax (VAT) of 19%, with import duties varying based on specific product classifications.

Belgium

1. Regulatory Authority: Federal Agency for Medicines and Health Products (FAMHP).

2. Import Registration Process: Medicines must be authorized by the European Medicines Agency (EMA) or FAMHP. Importers need a wholesale distribution authorization.

3. Estimated Timeline for Registration: The EMA's centralized procedure takes up to 210 days, while national procedures can vary but generally align with this timeframe.

4. Import Tariff/Duty for HS 30049099: Pharmaceuticals imported into Belgium are typically duty-free but subject to a VAT of 6%.

Dominican Republic

1. Regulatory Authority: Dirección General de Medicamentos, Alimentos y Productos Sanitarios (DIGEMAPS).

2. Import Registration Process: Requires submission of a registration dossier, including product samples and manufacturing information, to DIGEMAPS.

3. Estimated Timeline for Registration: The process can take 6 to 12 months, depending on the complexity of the product and the completeness of the application.

4. Import Tariff/Duty for HS 30049099: Pharmaceutical products are generally subject to a 0% import duty but may incur a VAT of 18%.

The demand for Formoterol, a long-acting β₂-agonist used in managing asthma and chronic obstructive pulmonary disease (COPD), is driven by several factors:

• Disease Prevalence: The global burden of respiratory diseases is significant. According to the World Health Organization (WHO), COPD was the third leading cause of death worldwide in 2019, causing 3.23 million deaths. Asthma affected an estimated 262 million people in the same year.

• Government Healthcare Programs: Many countries have implemented national health programs focusing on non-communicable diseases, including respiratory conditions. For instance, the United States' National Asthma Control Program aims to reduce the burden of asthma through surveillance and intervention strategies.

• Universal Health Coverage Expansion: Efforts to achieve universal health coverage have led to increased access to essential medicines. Countries like Sri Lanka have made significant strides in providing free or subsidized medications for chronic diseases through public health services.

• WHO Essential Medicines List Procurement: Formoterol is included in the WHO Model List of Essential Medicines, guiding countries in prioritizing procurement to ensure availability of critical treatments.

• Tender-Based Purchasing: Many governments and large healthcare providers procure medicines through competitive tendering processes, aiming to secure quality products at optimal prices. This approach is prevalent in countries like Algeria and Belgium, influencing the importation and distribution of Formoterol.

With 320 buyers across 81 countries, the market for Formoterol reflects a global need for effective respiratory treatments, underscoring opportunities for suppliers to meet diverse healthcare demands.